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Abstract
Colorectal cancer (CRC) is thought to be initiated by mutation of Adenomatous Polyposis
Coli (APC), a tumour suppressor gene mutant in more than 80% of all human CRC cases. Loss of
heterozygosity of the APC gene results in non-functioning alleles. This renders an APC protein
incapable of maintaining proper Wnt signaling - critical in intestinal stem cell (ISC) homeostasis
- preventing ISC differentiation and promoting a stem cell-like proliferative state. This increased
Wnt activity raises Wnt target genes, including AXIN2, MYC, and the stem cell marker (LGR5)
gene in tumours comparatively to adjacent tissue. Clock genes activate the transcription of their
own repressors in a transcriptional/translational feedback loop (TTFL), in which CLOCK/BMAL1
drive the expression of CRY and PER whose products in turn suppress CLOCK/BMAL1. A second
TTFL regulates BMAL1. The clock and its target genes confer rhythmic functions to many cellular
processes including intestinal proliferation. I hypothesized that tumours will have disrupted
circadian clock gene expression. To test this, APCmin/+ animal tumours and tissue were sampled
over 24 hours using RT-qPCR. This revealed that circadian genes were less expressed in tumours,
and that Wnt, cell cycle progression, and stem cell marker genes were more greatly expressed
in tumours compared to adjacent tissue. Also, I hypothesized that tumorigenesis would increase
under clock disruption. To test this, APCmin/+ were crossed with BMAL1 mice to create an APCmin
; BMAL1-/- mice. These mice have a 2-fold increase in tumour counts while average size of
tumours is smaller, implying disrupted clock fuels an increased induction of tumours. Together,
these data suggest that tumours suppress circadian clock function, and that completely
disrupted circadian clock function increases tumorigenesis.

iv

Dedication
I dedicate this project to my late father, Jean-Yves Losier, who surrendered to brain cancer glioblastoma. He will forever be a source of strength and courage in me. I also dedicate this to
my husband, Carlos Nunes, who guided and supported me throughout my journey.

v

Acknowledgements
Dr. Phillip Karpowicz
Principal advisor
Kyle Stokes
For his in information and guidance
Abrial Cooke
For her early work in establishing APCmin/+ model in our
lab
Celina Dibiasio
For her contribution to ZT4/ZT12 qPCR collaboration
Kathyani Parasram
For her general support and encouragement
Karpowicz undergraduate lab members
For their support and help in putting a smile on
everyone
Melissa Gabrieau
Animal Care Technician in Central Animal Care Facility
Deserea Overdulve
Animal Care Technician
Nancy Barkley
For her steadfast work as Graduate Secretary – also a
great conversationalist
Christine Côté
Administrative Financial Clerk in Biology

vi

Table of Contents
Declaration of Originality .................................................................................................................. iii
Abstract ............................................................................................................................................ iv
Dedication ......................................................................................................................................... v
Acknowledgements........................................................................................................................... vi
List of Figures, Images, and Tables ................................................................................................... viii
Chapter 1: Introduction ......................................................................................................................1
1.1

Cancer........................................................................................................................................... 2

1.2

Colorectal Cancer ......................................................................................................................... 3

1.3

Wnt signaling and intestinal epithelium homeostasis ............................................................... 6

1.4

Circadian Rhythms ....................................................................................................................... 9

1.5

Circadian Clock ...........................................................................................................................10

1.6

The clock and cancer/CRC .........................................................................................................12

1.7

Hypothesis and Specific Aims ....................................................................................................15

1.8

Materials and Methods .............................................................................................................16

Chapter 2 .............................................................................................................................................16
Chapter 3 .............................................................................................................................................20
Chapter 2 ......................................................................................................................................... 24
RNA analysis investigating time-dependent differences in Wnt pathway and circadian clock targets in
colorectal adenomas and adjacent healthy tissue ............................................................................. 24
Results .....................................................................................................................................................25
Chapter 3: ........................................................................................................................................ 36
Tumour burden with BMAL1 mutation in the APCmin/+ background .................................................... 36
Results .....................................................................................................................................................37
Chapter 4: ........................................................................................................................................ 44
Discussion and Future Directives ...................................................................................................... 44
Discussion and Future Directives............................................................................................................45
Conclusion ...............................................................................................................................................53
References ....................................................................................................................................... 54
Vita Auctoris .................................................................................................................................... 58

vii

List of Figures, Images, and Tables
Chapter 1
1.1 Adenoma to carcinoma progression sequence in colorectal cancer
1.2 Schematic representation of the adenomatous polyposis coli (APC) protein and mutation
histograms.
1.3 Wnt on and off signaling
1.4 The mammalian circadian gene network
1.5 Dissection procedure for Chapter 2
1.6 Intestinal tumour count images for Chapter 3
1.7 Intestinal tumours for Chapter 3
Table 1.1 Primer details used in qPCR.
Chapter 2
2.1 BMAL1 expression in Proximal intestine
2.2 BMAL1 expression in Distal intestine and Wt expression
2.3 Per2 expression in Proximal intestine
2.4 Per2 expression in Distal intestine and Wt expression
2.5 REVERB expression in Proximal intestine
2.6 REVERB expression in Distal intestine and Wt expression
2.7 cyclinD expression in Proximal intestine
2.8 cyclinD expression in Distal intestine and Wt expression
2.9 AXIN2 expression in Proximal intestine
2.10 AXIN2 expression in Distal intestine and Wt expression
2.11 cMyc expression in Proximal intestine
2.12 cMyc expression in Distal intestine and Wt expression
2.13 LGR5 expression in Proximal intestine
2.14 LGR5 expression in Distal intestine
2.15 Summary of Expression of studied genes at all timepoints.
Table 2.1 Summary of qPCR results for APC+/+
Table 2.2 Summary of qPCR results for APCmin/+
Chapter 3
3.1 Total tumour count
3.2 Tumours >1mm
3.3 Tumours < 1mm
3.4 Tumours > 1mm from all regions
3.5 Tumours < 1mm from all regions
3.6 H&E staining image from APCmin/+; BMAL1+/+
3.7 H&E staining image from APCmin/+; BMAL1-/3.8 Average of tumour sizes in intestinal regions

viii

List of Abbreviations and Nomenclature
APCmin/+

APC : Adenomatous Polyposis Coli ; min : multiple intestinal neoplasia

CRC

Colorectal Cancer

BMAL1

Brain and Muscle Arnt-Like 1 is protein that in humans is encoded by
the ARNTL gene (BMAL1)

Per2

period 2 gene involved in the positive arm of the molecular clock

Reverb-

Nuclear receptor gene alpha involved in the negative arm of the molecular
clock

GSK3β

Glycogen Synthase kinase 3β

CK1

Casein Kinase 1

SCN

Suprachiasmatic Nucleus

Myc

Myelocytomatosis oncogene

TCF/LEF

T cell factor/lymphoid enhancer family

CCG

clock-controlled genes

GAPDH

Glyceraldehyde 3-phosphate dehydrogenase

ATM

ATM serine/threonine kinase

CHK2

protein coded by Checkpoint kinase 2 gene

CBC

Crypt Base Columnar cells

LGR5

Leucine rich repeat containing G-protein coupled receptor 5

CSC

Columnar Stem cells

ix

Chapter 1: Introduction
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1.1 Cancer
Half of all Canadians will develop cancer in their lifetime and of these disease victims, 25%
will die from the disease. [1] Cancer is defined as a process in which normal cells change
progressively to transform into a neoplastic state. These cells acquire successive traits and
capabilities enabling them to change into a collective of tumorigenic tissue of different and
distinct cell types that interact and progress into invasive malignant cells . [2] There are eight
distinguishing traits in all cancers which contribute to tumour growth and metastatic
transformation. These core traits invariably include sustained proliferative signaling, evasion of
growth suppressors, resistance of cell death, causing replicative immortality, induction of
angiogenesis, activation of invasion and metastasis, reprogramming of energy metabolism, and
finally, evasion of the immune destruction. [2] Underlying these distinguishing traits is genomic
instability which fuels the advancement of these traits and the development of disease.
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1.2 Colorectal Cancer
Colorectal cancer (CRC) is the 2nd most common cancer and accounts for 13% of all
cancers in Canada [1]. Its incidence remains unchanged over the past 20 years with 1 in 14 men
and 1 in 16 women likely to develop CRC in their lifetime. Approximately  5% of the incidence
of CRC is due to an inherited germline mutation. [3] Studying inherited CRC has improved our
understanding of factors and mechanisms at play in the sporadic development of disease.
Tumorigenesis is a multistep process, and in CRC, tumours appear after an initial mutation in
Adenomatous Polyposis Coli (APC) gene. Subsequently, other activation of oncogenes such as
c-Myc followed by the inactivation of Tumour Suppressor Genes (TSGs), the latter having a
greater impact on progression of disease. [4]

The inherited form of disease, familial

adenomatous polyposis (FAP) is an autosomal dominant syndrome in which a germ-line
mutated APC allele is inherited. [3] Nevertheless, more than 80% of all human CRC cases are
initially caused by a somatic mutation of APC, a mammalian tumour suppressor gene. Somatic
APC gene mutations lead to a truncation in the APC protein and is believed to be an initiating
step in formation of a dysplastic crypt for the development of an adenoma. Both germ-line and
somatic mutations are within the same basic range of amino acid sequences on the protein for
Axin or β-catenin binding. Mutations leading to a truncated APC protein occur most often
before the Axin binding codons (the first serine alanine methionine proline (SAMP)) – at codon
1580 – and at an initial 3 of a 20 amino acid coding repeat regions responsible in β-catenin
binding. [5]
However, adenoma to carcinoma transitions need multiple steps in genetic instability to
occur as seen in Figure 1.1. In an incorporated Knudson “two-step” theory, biallelic APC gene loss
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has an impact on growth of sporadic adenomas. A cell with loss of heterozygosity would then
grow and proliferate into a small adenoma with some growth advantage. With increased
proliferation, there is increased genetic instability and other subsequent independent mutations
can occur, such as p53 or K-ras, driving increased progression in the transition from adenoma to
carcinoma. [3]
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Normal

Dysplastic
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Inactivation of APC

Adenomatous
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Mutation of K-Ras

Chromosome
instability

Carcinoma
Subsequent mutations

Figure 1.1 Model for Genetic progression in CRC .Inactivation of APC protein leads to a dysplastic crypt.
Progression of adenoma can occur upon other mutations driving an adenomatous lesion phenotype.
Chromosomal instability can then drive subsequent mutation in the adenoma to carcinoma transition.
Adapted from [3]

Figure 1.2 Schematic representation of the adenomatous polyposis coli (APC) protein and
mutation histograms. (a) The 2,843 – amino acid APC protein and a representation of its interacting
partners. In the amino-terminal central-third of APC, there are multiple independent 20-amino acid
repeats that are β-catenin and many Axin protein binding sites. (b) Germ-line mutation frequencies and
distribution in familial adenomatous polyposis patients in respect to APC-coding region. Nearly all
mutations result in a truncation of protein. Codons 1061 and 1309 are “hot spot” mutations. (c) Somatic
mutation frequencies and distribution in sporadic CRC. A mutation cluster region accumulate the most
mutations. Codons 1309 and 1450 are “hot spot” mutations. Modified from [3].
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1.3 Wnt signaling and intestinal epithelium homeostasis
APC protein is a key negative regulator in Wnt signaling: in the absence of Wnt ligand, APC
protein forms a signaling destruction complex that targets cytosolic β-catenin for degradation.
APC complexes with the protein Axin in order to promote a 2-step phosphorylation of β-catenin
at several N-terminal residues– first by the enzyme casein kinase 1 and then by glycogen synthase
kinase 3β (GSK3β). These phosphorylation steps target β-catenin for proteasomal degradation.
Conversely, in the presence of a Wnt ligand, a transmembrane Frizzled protein and a low-density
lipoprotein receptor-related protein (LRP) form a complex that sequesters GSK3β and Axin from
the destruction complex which permits newly synthesized cytosolic β-catenin stabilization and
accumulation triggering its translocation to the nucleus. [4] [5] Once there, β-catenin binds to T
cell factor/lymphoid enhancer family (TCF/LEF) and converts it to an activated form for many
growth genes, notably the oncogene c-Myc, cell cycle regulator cyclin D, the stem cell marker and
agonist of the Wnt pathway LGR5, as well as Axin2 which is a global Wnt transcriptional target.
[6] [4] [7] The movement of β-catenin from the cytoplasmic to nuclear emplacement has yet to
be completely understood. A comprehensive schematic of Wnt signaling is presented in Figure
1.3 below.
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Figure 1.3. Wnt on and off signaling modified from [5] When Wnt signaling is off, APC
destruction complex targets β-catenin for destruction and downstream target genes are not
transcribed. When Wnt signaling in on, the APC complex is sequestered, synthesized β-catenin is
stabilized and can translocate to the nucleus and upregulate downstream target genes and
induce a Wnt phenotype.
The small intestine epithelium is a classic model in mammalian Wnt signaling. The villi extend
into the intestinal lumen and are the most rapidly renewed tissue in adult mammals with an
entire turnover rate of 4-5 days. [4] Each crypt is located at the base of these villi and extends
into the submucosal membrane as a droplet-like invagination of cooperating cells. At the base of
the crypts are differentiated Paneth cells and the intestinal Wnt-responsive intestinal stem cells,
also known as LGR5 crypt base columnar (CBC) cells. Each crypt contains approximately 15 LGR5
CBCs. [8] Local signaling by Paneth cells, which are strategically interspersed with CBCs in the
crypt base, of both Wnt ligands and Rspondin ligands (whose receptor target is LGR5) act on ISCs
to drive Wnt signaling [9]. Transit amplifying cells – progenitor cells that move upward and begin
7

to differentiate into the various specialized cells of the intestine - populate the villi of secretory
(goblet, enteroendocrine, tuft and previously mentioned Paneth cells) or absorptive
(enterocytes) cells. Paneth cells are the exception to this lineage differentiation model and do
not migrate out of the crypt but rather migrate back down to the crypt base. [10] As an influx of
new cells move up the villi, cells at the tip encounter an apoptotic fate and are steadily removed.
Wnt signaling prevents the differentiation of ISCs in the stem cell niche, and the
constitutive activation of the Wnt pathway causes cells that move up the epithelium to maintain
ISC-like phenotypes including LGR5 expression and mitotic growth. [11] This is believed to be an
important initial contributing factor to the development of CRC.
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1.4 Circadian Rhythms
A circadian rhythm is a 24-hr periodicity of behavioural and physiological processes that
occur in organisms based on the Earth’s 24-hour rotation. Half of the Earth’s surface is exposed
to the Sun’s light, creating day and night which has influenced daily activity and evolution as we
know it. An organism’s ability to adapt its metabolism and activities based on the day-night cycle
is thought to increase its fitness over time [12] [13] [14]. The temporal regulation of the 24-hour
cycle, for example eating during the daytime and fasting at night, has influenced evolution on the
cellular level. These day-night directives have contributed to cell specific circadian oscillators in
a wide range of lifeforms. [15] A circadian rhythm occurs in virtually all cells of the body in a cellautonomous, gene-driven, fashion orchestrated by the expression of genes, termed circadian
clock genes [16].
The circadian clock is organized hierarchically in mammals. The central circadian
orchestration is directed by the suprachiasmatic nucleus (SCN) located deep in the central region
of the hypothalamus where it receives light cues via the optic nerve. The SCN is very sensitive to
light impulses. Phase shifts in rhythmicity can occur accordingly [17] and this information is sent
to peripheral clocks of the body, synchronizing them. Therefore, light cues incorporated into the
body from the environment via this central clock entrain the system as a whole via neuronal and
hormonal messages that travel systemically to induce circadian rhythms in peripheral tissues [17]
This permits systemic rhythmicity and adaptability to new or changing environments imparting
fitness of the system as a whole. Peripheral clocks of the body are composed of cell-autonomous
oscillators that employ the same genetic clock machinery, but the output differs according to the
organ system in question.
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1.5 Circadian Clock
In the mammalian transcriptional-translational feedback loop (TTFL), there is a core
transcription factor termed the Brain And Muscle ARNT-Like 1 (BMAL1). This is a basic helix-loophelix protein which dimerizes with the transactivator CLOCK to bind to the E-Box promoter site
for the transcription of clock genes PERIOD and CRYPTOCHROME generating their proteins, PER1,
PER2, PER3, and CRY1 and CRY2, respectively. These proteins form a negative feedback repressor
complex [17] that accumulates in the cytoplasm to then translocate back to the nucleus where it
turns off its own gene transcription. In addition, there is a second feedback loop where
BMAL1/CLOCK dimer regulates the transcription ofNr1d1/Nr1d2 nuclear receptors REVERB and
REVERBβ respectively which will impart a repression of BMAL1 gene transcription. Overall these
two systems of feedback, result in the oscillatory expression of core circadian genes, creating
rhythmic transcription cycles.
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Figure 1.4 Schematic of the circadian clock network. The core circadian clock mechanism is a cellautonomous transcriptional translational feedback loop linking CLOCK and BMAL1 and their target genes
Per1,2 and Cry1,2, whose translated proteins form a repressor complex that creates a feedback loop.
Additionally, there are other feedback loops driven by the core clock gene dimers CLOCK:BMAL1. A first
such loop comprises REVERBs and RORs that are antiphasic to BMAL1 gene expression and that repress
BMAL1 transcription. CLOCK:BMAL1 also govern downstream target gene expression termed clockcontrolled genes (CCG) which cause rhythmic biological processes in various tissue. Post translational
modification and phosphorylation of Cry and Per target them for ubiquitination, allowing CLOCK:BMAL1
to once again bind to E-boxes and begin again the cycle. Image modified from [15]
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1.6 The clock and cancer/CRC
There is an increased incidence of cancer in people exposed to chronic disrupted circadian
rhythms, such as shift workers. In recent years, epidemiological studies have revealed a slight to
moderate increase in risk for breast, colon, endometrial epithelial malignancies as well as nonHodgkin’s lymphoma in longtime night workers and shift workers. [18] [19] It is unclear if this
greater incidence is causal or incidental. The molecular links between the circadian clock and
cancer remain unclear. Some studies have shown that loss of circadian function increased
tumorigenesis while other conflicting research has shown that disrupting core clock components
can decrease tumour growth and so this remains a contested area of study.
A disrupted circadian organization has been linked to some of the hallmarks of cancer.
[20] There is evidence that Per1 connects the circadian system and cell death, its overexpression
sensitizes cancer cells to DNA damage-induced apoptosis while, inversely, its silencing conveys a
blunted apoptotic progression. [21] Upregulation/deregulation of the proto-oncogene cMyc is
often associated with human cancers – where it plays a key role in cell growth. cMyc is a
transcription factor whose structure is very similar to both the structures of CLOCK and BMAL1
transcription factors. All are basic Helix-loop-Helix (bHLH) transcription factors that compete for
binding to E-boxes in the promoter of many target genes, with 574 overlapping gene binding
sites. [22] [23] Myc and its dimer partner MAX are functionally dominant over CLOCK/BMAL1 for
E-box binding [22]. Elevated Myc expression is associated with the poorest clinical outcome in
neuroblastoma patients as is elevated REVERBa. [23] Myc abnormal expression, as occurs in
cancerous cells, results in an increase of target genes involved in metabolic processes such as
glycolysis, oxidative metabolism, as well as mitochondrial and ribosomal biogenesis and cell cycle
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regulation [24] As mentioned previously, genomic instability fuels cancer progression and can
cause or be the consequence of transformation. Genomic instability has also been linked to Per1.
[25] [21] One study investigated whether Per1 could influence the DNA damage response by
modulating the ATM pathway and its downstream effector CHK2, a key cell cycle checkpoint
protein. It was concluded that Per1 was necessary for effective activation of CHK2 when DNA was
damaged through double strand breaks. [21] Yet another lab looked at the impact of Per1 and
Per2 on tumour growth and circadian organization and found that that tumour growth is
coordinated by the circadian clock in vivo, and that depletion of these 2 genes enhanced tumour
growth rate at certain times of the day. [20] Important to this thesis, the APCmin/+ mouse model,
has also been used to investigate circadian rhythms’ disruption and its impact on colorectal
cancer progression.

One lab demonstrated that a Per2 mutation accelerated APCmin

tumorigenesis, increasing b-catenin levels and its target protein cyclin D. [26] Another found loss
of Per2 showed a neoplastic growth phenotype [27]. Finally, there is some evidence that the 3rd
homolog to the human Period protein, PER3, is downregulated in chronic myeloid leukemia, a
variant PER3 genotype was associated with increased breast cancer risk, and its altered gene
expression was identified in 203 Colorectal cancer patient samples. [28] [29] [30] Similarly, a
recent study showed transplanted B16 cell tumours had suppressed clock genes but triggering
circadian clock in these cells function inhibits tumorigenesis, slowing down tumour growth [31]
However, since there are three homologs of the PER gene and these studies did not manipulate
all Per genes simultaneously, the circadian clock is completely functional in the animals used in
these studies suggesting it is not clock function that impacts cancer, but rather a non-clock
function for the Per genes.
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As mentioned above, research has unveiled conflicting views on the circadian rhythms’
impact on tumorigenesis. One such study found that suppressing the clock gene BMAL1
promotes differentiation of Leukemia Stem Cells in acute myeloid leukemia (AML) and decreases
the proportion of actively dividing cells, thereby reducing tumour progression [32]. This suggests
that loss of clock gene activity decreases cancer rather than increases cancer. Another study
found that overexpression of Per1 was shown to induce increased expression of cMyc in HCT116
cancer cell lines with a Per1 expression vector (HCT/PER1). [21] Most importantly, recent studies
found that when p53 is mutated, as it is in more than 50% of cancers, in CRY1/2-/- mice enhances
intrinsic (mitochondrial) and extrinsic (cytokines) apoptosis. These p53; CRY1/2 triple mutants,
when treated with UV-mimetic agents (such as the chemotherapeutic oxaliplatin), actually have
increased survival probabilities likely due to p53-independent intrinsic apoptosis. [33] Indeed, in
a heroic effort to validate the previous research on Per genes mentioned above, a study tested
both normal and irradiated Per1-/- and Per2 -/- mice only to find that these clock mutations alone
do not make mice more tumour-prone. [34] These studies made careful tests of Per function by
backcrossing mice on the same genetic background, a major source of error in the previous
studies examining clock function. This body of differing data offers confounding information.
Therefore the role of the circadian clock in cancer disease progression is an open
question.
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1.7 Hypothesis and Specific Aims
The major objectives of this study were to investigate how tumours behave in comparison to
normal intestinal tissue as well as to investigate tumorigenesis in a clock-dead CRC mouse model.
I first hypothesized that transformed cells would have disrupted expression of circadian clock
gene transcription. I furthermore hypothesized that tumorigenesis would increase under clock
disruption in the APCmin/+ mouse cancer model. To test these hypotheses, the following aims were
pursued:
1. Investigate, using RT-qPCR, whether there are time-dependent differences in Wnt
pathway targets, such as cMYC, AXIN2, and LGR5 as well as cell cycle promoter CyclinD,
and whether there are differences in circadian clock components PER2, BMAL1, and REVERB within tumorous cells and the surrounding normal tissue in littermate APCmin/+
animals (addressed in Chapter 2).
2. Investigate, through visual investigation and H&E staining, the impact of a disrupted
circadian rhythm on tumorigenesis using the APCmin/+ mouse model system. Circadian
rhythm disruption was carried out genetically, and tumours throughout the intestine
were counted and measured (addressed in Chapter 3).
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1.8 Materials and Methods
Chapter 2
Animals and Housing:
Mice from the Jackson Laboratory (BL/6J-ApcMin/J Catalog Number. /ID: 002020) were bred
to obtain APCmin/+ genetic makeup. They were bred and maintained with wild type littermates
until 3 months. All samples were obtained at 3 months of age. Conditions in the animal quarters
were maintained with a constant 12-hour light and 12-hour dark photoperiod. All Animal Care
Committee (ACC) guidelines and University of Windsor Research Ethics Board for Animal
Protocols were strictly respected. Water was sterile, and feeding was ad libitum.

Tissue Collection:
Animals were sacrificed at 4-hour intervals on the 24-hour cycle. Sample size was 5
APCmin/+ and 3 APC +/+ per timepoint. A total of 6 tumours and 6 adjacent tissue samples were
taken per APCmin/+ animal (3 from the proximal intestine and 3 from the distal intestine) as well
as 1 sample of tissue consisting of 1 blend of proximal and distal intestine from the negative
control APC +/+. Following CCAC protocol, CO2 was administered followed by isolation of intestine.
Whole intestine segments were stored in 8mL of RNAlater (Qiagen Cat No./ID: 74106) solution
for 24 hours at 4°C followed by long-term storage at -80°C. Intestine samples were collected at
7 am, 11 am, 3 pm, 7 pm, 11 pm, and finally 3 am, or ZT0, ZT4, ZT8, ZT12, ZT16, and ZT20
respectively. See figure below for visual representation of steps described above.
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n = 5 animals at 4 hour intervals (6
timepoints)
In RNAlater
for analysis

Flushed with PBS

6 tumours and adjacent tissues / animal
(3 from proximal 3 from distal regions of
intestine)
Total: 360 samples tested

Figure 1.5 Dissection of animals in preparation for RNA analysis. 6 timepoints, each with
5 animals were analyzed. In each animal, 6 adenomatous overgrowths as well as 6 adjacent
normal-looking epithelial tissue samples were extracted. 360 Tumour and Tissue samples total
were analyzed as well as 18 APC+/+ negative controls.

RNA extraction
RNA extraction was accomplished by placing intestine sections on a Sylgard Plate (Dow
Corning) along with some RNA later to maintain tissue integrity. Using a Zeiss Semi 2000
sterioscope and its magnitude of 2.5x, tumours no greater than 27mm3 were sampled and placed
in bullet blender tubes (Next Advance) containing 0.9 - 2.0 mm stainless steel beads (SS14B-RNA)
in 30 µl of RNA later and kept on ice. As described above, 3 tumours from proximal and from
distal regions were excised along with a tissue sample from the adjacent intestinal epithelium
without tumour formation. Total samples therefore per animal was 12 (n = 6 tumours and n = 6
tissue). All samples were collected using sterile technique with a thorough cleaning using 70%
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ethanol on instruments between samples in an RNase-free space ensured by wiping all
equipment and work surfaces with RNAzap (Qiagen Cat No./ID: 74106). RNAeasy RNA extraction
kit was used and hence forth all RNA extraction refers to Qiagen Cat No./ID: 74106. Once all
samples were collected, RNAlater was removed from bullet blender tubes, careful not to disturb
the sample, and 600µl β-Mercaptoethanol (Aldrich, Cat No./ID: M6250) and RLT buffer mix at a
1µl:100µl ratio, respectively. RNA-free filter pipette tips were used throughout the entire RNA
extraction process. In 600 µl β-Mercaptoethanol : RLT buffer mix, samples were homogenized in
a bullet blender for 4 minutes at speed 8. After a minute pause, samples were again subjected to
shredding at speed 10 for 2 minutes. Subsequently, they were spun at 14 800 RPM for 3 minutes
at 4 oC. Supernatant was removed and equal parts (600 µl) of 70% ethanol in RNAse-free water
was added making sure to mix well with the supernatant. Supernatant: 70 % ethanol mix was
added in 2 batched of 600 µl to an RNAeasy mini spin column and spun at 11 000 RPM for 1
minute at 22 oC, with discard of lysate flow-through.
250 µl of RW1 Buffer was added, spun at 11 000 RPM for 1 minute followed DNAse
treatment for 15 minutes at room temperature in a 10 µl: 70 µl RDD buffer (Qiagen Catalog
No./ID: 79254) ratio. After this incubation, 350 µl RLT butter was added and samples were spun
at 11 000 RPM discarding the flow-through. This was followed by twice adding 500 µl RPE buffer,
spinning at 11 000 RPM and discarding the flow-though. Prior to adding water for the final RNA
extraction step, samples were dried by spinning at 11 000 RPM in a fresh elution tube for 1
minute. Columns were placed in a new labeled 1.5 mL Eppendorf tube and 40 µl of RNAse-free
water (Ambion, Cat No./ID: AM9930) was added and incubated for 1 minute at room
temperature. Samples were spun at 11 000 RPM. This was repeated. Extracted RNA was collected
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labeled Eppendorfs and immediately placed on ice. Employing a NanoDrop ND-1000
Spectrophotometre (ThermoScientific), 1 µl of each sample was analyzed for its yield in RNA
concentration in ng/µl.
cDNA synthesis was performed using 0.5 µg of RNA in each 20µL sample of cDNA using
IScript protocol. Amplified genes in samples included gene expression of GAPDH (used as an
expression control as well as a normalization reference for all gene expression levels), BMAL1,
PER2, REV-ERBα, CycD, cMYC, AXIN2, and LGR5. A primer set (PrimerBank) for each gene of
interest was amplified at >90% efficiency, previously determined in our lab. The following primers
were used:
Target

Forward Primer

Reverse Primer

GAPDH

AGGTCGGTGTGAACGGATTTG

TGTAGACCATGTAGTTGAGGTCA

BMAL1

TGACCCTCATGGAAGGTTAGAA

GGACATTGCATTGCATGTTGG

PER2

GAAAGCTGTCACCACCATAGAA

AACTCGCACTTCCTTTTCAGG

Reverb-α

TGAACGCAGGAGGTGTGATTG

GAGGACTGGAAGCTATTCTCAGA

CycD

GCGTACCCTGACACCAATCTC

CTCCTCTTCGCACTTCTGCTC

cMYC

ATGCCCCTCAACGTGAACTTC

GTCGCAGATGAAATAGGGCTG

AXIN2

TGACTCTCCTTCCAGATCCCA

TGCCCACACTAGGCTGACA

LGR5

CCTACTCGAAGACTTACCCAGT

GCATTGGGGTGAATGATAGCA

Table 1.1 Primer details used in qPCR.
RT-qPCR was done using a 384 well plate with 10 µl in each well. Each well consisted of 5
µl of 2X QuantiIect SYBR Green (Qiagen Catalog No./ID: 204141), 3.2 µl RNAse-free water and 0.4
µl each or forward and reverse primers at a 10pmol/µl concentration. To this, 1 µl of the cDNA
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sample was added. To ensure accuracy, wells were plated in duplicates, and data was used when
duplicate critical threshold was <0.5 cycle standard deviation. Quantification was done using
Viia7 Real-Time PCR system (Thermo Fisher Scientific). Critical threshold of >30 cycles (very low
product abundance) were not used in the quantifications presented.
Chapter 3
Animal Housing:
Mice from the Jackson Laboratory (C57BL/6J-ApcMin/J Catalog Number/ID: 002020) were
bred to obtain the APCmin/+ genetic makeup. Male APCmin/+ mice, wild type for the BMAL1 gene,
were crossed with a second strain of BMAL1+/- female mice (Jackson Laboratory B6.129Arntl tm1
Bra/J Catalog Number/ID 009100), wild type for the APC gene. These two genetic backgrounds
were crossed for > 4 generations of backcrosses until they yielded male offspring of APCmin/+;
BMAL1+/- genotype as well as females of APC+/+ ; BMAL1+/- genotype. These littermates were
then backcrossed to obtain multiple generations of offspring containing the 4 genetic profiles for
this project: APCmin/+ ; BMAL1-/- (n=12), APC+/+ ; BMAL1+/+ (n=12), APC+/+ ; BMAL1-/- (n=15), and
APCmin/+; BMAL1+/+ (n=11). All littermates were kept together until they reached maturation at 3
months of age at which point samples were obtained at 2 timepoints in the 24-hour cycle – at
ZT4 (morning) or ZT12 (evening). Conditions in the animal quarters were maintained with a
constant 12-hour light and 12-hour dark photoperiod, all Animal Care Committee (ACC)
guidelines and University of Windsor Research Ethics Board for Animal Protocols were strictly
respected. Temperature and humidity were maintained at 22 ̊C and 55%, respectively and sterile
water and feeding was ad libitum.
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Tissue Acquisition:
Animals were sacrificed by CO2 asphyxiation at 2 ml/min for 10 minutes followed by
cervical dislocation. Body cavity was opened, and full intestine removed from start of duodenum
to end of ileum. Intestine was cut into 3 approximately even segments. A blunted 25g needle
was inserted into the distal regions of each segment intestinal lumen was flushed using cold 1x
Gibco Phosphate-buffered saline (PBS) then fixed for 2 hours in 4% paraformaldehyde at room
temperature. Intestines were then rinsed 3X in PBS then allowed to dehydrate in 30% sucrose
overnight or longer.

A

B

A

Figure 1.6 Intestinal Tumour Count (A) Entire length of intestine was laid out and measured for
partitioning into 4 equal segments. (B) Individual cut third segments were laid and tumour were
counted in the measured quarter partitions.
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Figure 1.7 Intestinal Tumours. Example of tumours greater than 1 mm are circled in red while
less than 1mm in blue. A glass rod yardstick of 1mm in diameter was used to decipher size, if
questionable.
Quantification:
Placing intestine sections on a Sylgard Plate (Dow Corning), the entire length of intestine
was measured (Figure 1.6 A) to determine the total length. Adenomas/tumours were counted
(Figure 1.6 B) in each quarter of this length using a Zeiss 2000 stereoscope. Tumours were
qualified as being either greater than 1mm or less than 1mm in diameter (Figure 1.7) Intestinal
samples were then Swiss-rolled and imbedded in optimal cutting temperature compound (OCT,
Tissue-Tek, Sakura) and sectioned at 10µm and allowed 1 hour to dry before being stored at -20
oC. Slides were removed from the 20 oC freezer and allowed 30 minutes to thaw. Slides were then

stained for Hematoxylin and Eosin. First, slides were immersed in Ehrlich’s Hematoxylin Solution
(26040-05, EMS) for 5 minutes, removed and incubated in acid alcohol (700mL 100% ethanol,
390mL distilled H2O, 10mL HCl) for 30 seconds then moved to a wash of 0.1% Sodium Bicarbonate
for one minute. Following the bicarb wash, slides were washed for 5 minutes in running tap
water. Slides were then quickly washed in distilled water for 30 seconds. Second incubation in
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Aqueous Eosin Y (1%, 26051-10, EMS) was for 5 minutes. Again, slides were washed in running
tap water for 5 minutes then quickly washed in distilled water for 30 seconds. Slides were then
dehydrated in a 2-step 95% ethanol each for 2 minutes and subsequently dehydrated more in a
2-step 100% ethanol bath for 2 minutes each. They were then cleared twice for 15 minutes in
Histoclear (64110-01, EMS) and mounted in Clearium, (13520-11, EMS) mounting media. Slides
were scanned using AXIOscan.
H&E slides were scanned using Axio Scan.Z1 to locate all tumours on a slide from APCmin/+
; BMAL1-/- (n=12) and APCmin/+ ; BMAL1+/+ (n=11). The genotypes APC+/+ ; BMAL1+/+ (n=12) and
APC+/+ ; BMAL1-/- (n=15) did not have any significant tumours to justify staining and scanning of
these samples.
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Chapter 2
RNA analysis investigating time-dependent differences in Wnt
pathway and circadian clock targets in colorectal adenomas and
adjacent healthy tissue

24

Results
To assess expression levels of target genes in APCmin/+ induced tumours, we collected
tumour and tissue samples (n=30 animals), extracted RNA, made cDNA and ran RT-qPCR analysis
with GAPDH as a normalization control. Tissues were used as negative controls in APCmin/+
animals. However, the tissue samples were still from the tumour-prone mice. Therefore, APC+/+
littermates (n=18) were also sacrificed and expression of BMAL1, PER2, REVERB, CyclinD, cMyc,
and AXIN2 were analyzed relative to GAPDH normalization control. Results or RT-qPCR showed
that tumours, except for a few outliers, showed lower expression of BMAL1 and PER2 clock
genes, and to a lesser degree REVERB compared to the tissue adjacent to the tumour. We also
saw an increased expression of Wnt, cell cycle progression, and stem cell marker genes. Tumours
exhibited circadian rhythms like tissue and Wt, but these rhythms were dampened. Results are
summarized in Tables 2.1 and 2.2 following the figures below.
The proximal and distal regions of the intestine were analyzed separately because these
are functionally and morphologically distinct tissue regions. Expression of BMAL1 was less in 70
% of proximal tumours (fig 2.1) and 90% in distal tumours (fig 2.2), and was at its highest
between ZT20 and ZT0 and its lowest between ZT8 and ZT12, in all samples. This mostly
corresponds to BMAL1 expression in our negative control (figs 2.2), with a slightly later peak
expression in the Wt. Expression of Per2 was less in nearly 86% of proximal tumours (fig 2.3)
and 90% in distal tumours (fig 2.4). Inversely to BMAL1, peak expression of Per2 in APCmin/+
animals was at ZT12 and trough between ZT0-4. Our negative control had peak expression at
ZT16 (figs 2.4) This constitutes a slight phase shift, meaning peak expression has advanced
slightly to earlier in the cycle in the APCmin/+ . Results for REVERB expression levels between
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tumours and tissue were more mixed. Tumours in the proximal intestine expressed this gene
less in only 63% of samples (fig 2.5). In the distal intestine, 71% of tumours expressed less
REVERB than the tissue samples (fig 2.6). REVERB has an expression peak at ZT8 and a trough
between ZT0, which compares to APCmin/+ expression. CyclinD expression was greater in 96% of
tumours in the proximal intestine (fig 2.7) and in 81% of distal tumours (fig 2.8). The APCmin/+
and Wt expression of cyclinD did not have significant expression rhythmicity. Axin2 expression
was more greatly expressed in 88% of proximal tumours (fig 2.9) and 82% of distal tumours
(2.10). APCmin/+

and Wt animals had significant variations in expression levels between

timepoints, but not in a 24-hour period circadian manor. This gene’s expression could be
ultradian in nature, meaning shorter <24h repeated cycles within a day. cMyc expression had
the most pronounced expression findings. cMyc was not rhythmic in APCmin/+ samples, but there
was significant variation between the timepoints in the Wt tissue. 98% of tumours more greatly
expressed cMyc in the proximal intestine (fig 2.11) and 96% did so in the distal region (fig 2.12).
Lastly, 91% of tumours more greatly express the stem cell marker LGR5 in proximal tumours (fig
2.13) as does 89% of distal tumours (fig 2.14). Overall these results showed that clock gene
function is lower in tumour than in surrounding wildtype tissue, and that Wnt pathway
dysfunction is higher in tumours than in surrounding tissue.
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BMAL1 expression is less in 70% of Proximal Tumours
0.07

Tumour
Tissue

0.06

0.05

0.05
Expression
(Relative to GAPDH)

0.06

Wt BMAL1

0.04

0.03

Expression
(Relative to GAPDH)

Expression
(Relative to GAPDH)

0.07

BMAL1 expression is less in 90% of Distal Tumours
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BMAL1 expression in APC+/+ negative
control. Graph shows n=18 tissue
samples. Quantification of BMAL1
expression relative to GAPDH by qPCR
in samples.
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Figure 2.1 BMAL1 expression is reduced
samples in 70% of proximal tumours.
Graph shows n=90 tumours and n=90 tissue in APC min/+ mice.
Quantification of BMAL1 expression relative to GAPDH by qPCR in proximal
tumours (grey) and tissues (black). BMAL1 is a circadian clock gene and its
diurnal rhythm in these samples shows a peak at ZT20 and a trough at ZT8.
The diurnal changes in BMAL1 in tissue is significant (ANOVA, F (5, 84) =
30.13 P<0.0001) and the diurnal change in BMAL1 in tumour is also
significant (ANOVA, F (5, 84) = 16.75 P<0.0001) Paired T-test indicates that
70% of samples measured have significantly lower expression of BMAL1 in
tumours (p<0.0001). There is a high variability in tumours and tissue.
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Figure 2.2 BMAL1 expression is reduced
in 90% of distal tumours. Graph
samples
shows n=90 tumours and n=90 tissue in APC min/+ mice. Quantification of
BMAL1 expression relative to GAPDH by qPCR in distal tumours (grey) and
tissues (black). BMAL1 is a circadian clock gene and its diurnal rhythm in
these samples shows a peak at ZT20 and a trough at ZT8. The diurnal
changes in BMAL1 in tissue is significant (ANOVA, F (5, 84) = 29.07,
P<0.0001) and the diurnal change in BMAL1 in tumour is also significant
(ANOVA, F (5, 84) = 16.32, P<0.0001). Paired T-test indicates that 90% of
samples measured have significantly lower expression of BMAL1 in tumours
(p<0.0001). There is a high variability in tumours and tissue.
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PER2 expression is less in 90% of Distal Tumours
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PER2 expression is less in 85.6% of Proximal Tumours
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Figure 2.3 Per2 expression is reduced in 85.6% of proximal tumours. Graph
shows n=90 tumours and n=90 tissue APC min/+ mice. Quantification of Per2
expression relative to GAPDH by qPCR in proximal tumours (grey) and tissues
(black). Per2 is a circadian clock gene and its diurnal rhythm in these samples
shows a peak at. The diurnal changes in Per2 in tissue is significant (ANOVA, F
(5, 84) = 21.57, P<0.0001) and the diurnal change in Per2 in tumour is also
significant (ANOVA, F (5, 84) = 16.75, P<0.0001). Paired T-test indicates that
85.6% of samples measured have significantly lower expression of Per2 in
tumours (p<0.0001). There is a high variability in tumours and tissue.
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Per2 expression in APC+/+ negative
control. Graph shows n=18 tissue
samples. Quantification of Per2
expression relative to GAPDH by qPCR
in samples.
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Figure 2.4 Per2 expression is reduced in 90% of distal tumours. Graph shows
n=90 tumours and n=90 tissue APC min/+ mice. Quantification of Per2
expression relative to GAPDH by qPCR in distal tumours (grey) and tissues
(black). Per2 is a circadian clock gene and its diurnal rhythm in these samples
shows a peak at ZT12. The diurnal changes in Per2 in tissue is significant
(ANOVA, F (5, 84) = 15.17, P<0.0001) and the diurnal change in Per2 in tumour
is not significant (ANOVA, F (5, 84) = 2.106, P=0.726). Paired T-test indicates
that 90% of samples measured have significantly lower expression of Per2 in
tumours (p<0.0001). There is a high variability in tumours and tissue.
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REVERBa expression is less in 71% of Distal Tumours

REVERBa expression is less in 63% of Proximal Tumours
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Figure 2.5 REVERB expression is reduced in 63% of proximal tumours.
Graph shows n=90 tumours and n=90 tissue APC min/+ mice. Quantification
of REVERB expression relative to GAPDH by qPCR in proximal tumours
(grey) and tissues (black). REVERB is a circadian clock gene and its diurnal
rhythm in these samples shows a peak at ZT8. The diurnal changes in
REVERB in tissue is significant (ANOVA, F (5, 84) = 3.903, P=0.0031) and the
diurnal change in REVERB in tumour is also significant (ANOVA, F (5, 84) =
26.8, P<0.0001). Paired T-test indicates that 63% of samples measured have
significantly lower expression of REVERB in tumours (p<0.0001). There is
a high variability in tumours and tissue.
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Figure 2.6 REVERB expression is reduced in 71% of distal tumours. Graph
shows n=90 tumours and n=90 tissue APC min/+ mice. Quantification of
REVERB expression relative to GAPDH by qPCR in distal tumours (grey)
and tissues (black). REVERB is a circadian clock gene and its diurnal
rhythm in these samples shows a peak at ZT8. The diurnal changes in
REVERB in tissue is significant (ANOVA, F (5, 84) = 56.7, P<0.0001) and the
diurnal change in REVERB in tumour is also significant (ANOVA, F (5, 84)
= 4.225, P=0.0018). Paired T-test indicates that 71% of samples measured
have significantly lower expression of REVERB in tumours (p<0.0001).
There is a high variability in tumours and tissue.
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CyclinD expression is greater in 81% of Distal Tumours
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CyclinD expression is greater in 96% of Proximal Tumours
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in samples.

0.01

0.00

ZT0

ZT4

ZT8

ZT12

ZT16

ZT20

Figure 2.7 cyclinD expression is increased
samples in 96% of proximal tumours.
Graph shows n=90 tumours and n=90 tissue APC min/+ mice.
Quantification of cyclinD expression relative to GAPDH by qPCR in
proximal tumours (grey) and tissues (black). Paired T-test indicates that
96% of samples measured have significantly lower expression of cyclinD
in tumours (p<0.0001). There is a high variability in tumours and tissue.
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Figure 2.8 cyclinD expression is samples
increased in 81% of distal tumours.
Graph shows n=90 tumours and n=90 tissue APC min/+ mice.
Quantification of cyclinD expression relative to GAPDH by qPCR in distal
tumours (grey) and tissues (black). Paired T-test indicates that 81% of
samples measured have significantly lower expression of cyclinD in
tumours (p<0.0001). There is a high variability in tumours and tissue.
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AXIN2 expression is greater in 82% of Distal T umours

AXIN2 expression is greater in 88% of Proximal Tumours
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expression over a 24-hour period is
significant in the Wt (ANOVA, F (5, 12) =
4.017, P<0.0225)
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Figure 2.9 AXIN2 expression is increased in 88% of proximal tumours.
Graph shows n=90 tumours and n=90 tissue APC min/+ mice.
Quantification of AXIN2 expression relative to GAPDH by qPCR in
proximal tumours (grey) and tissues (black). Paired T-test indicates that
88% of samples measured have significantly lower expression of AXIN2
in tumours (p<0.0001). There is a high variability in tumours and tissue.

ZT0

ZT4

ZT8

ZT12

ZT16

samples

ZT20

Figure 2.10 AXIN2 expression is increased in 82% of distal tumours.
Graph shows n=90 tumours and n=90 tissue APC min/+ mice.
Quantification of AXIN2 expression relative to GAPDH by qPCR in distal
tumours (black) and tissues (grey). Paired T-test indicates that 82% of
samples measured have significantly lower expression of AXIN2 in
tumours (p<0.0001). There is a high variability in tumours and tissue.
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cMYC expression is greater in 98% of Proximal Tumours

cMYC expression is greater in 96% of Distal Tumours
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Figure 2.11 cMyc expression is
98% of proximal tumours.
Graph shows n=90 tumours and n=90 tissue APC min/+ mice.
Quantification of cMyc expression relative to GAPDH by qPCR in
proximal tumours (grey) and tissues (black). Paired T-test indicates that
98% of samples measured have significantly lower expression of cMyc
in tumours (p<0.0001). There is a high variability in tumours and tissue.

cMyc expression in APC+/+ negative
control. Graph shows n=18 tissue
samples. Quantification of cMyc
expression relative to GAPDH by qPCR in
samples. The changes in cMyc
expression over a 24-hour period is
significant in the Wt (ANOVA, F (5, 12) =
5.959, p = 0.0054).
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Figure 2.12 cMyc expression is increased
samples in 96% of distal tumours.
Graph shows n=90 tumours and n=90 tissue APC min/+ mice.
Quantification of cMyc expression relative to GAPDH by qPCR in distal
tumours (grey) and tissues (black). Paired T-test indicates that 96% of
samples measured have significantly lower expression of cMyc in
tumours (p<0.0001). There is a high variability in tumours and tissue.
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LGR5 expression is greater in 91% of Proximal Tumours
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LGR5 expression is greater in 89% of Distal Tumours
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Figure 2.13 LGR5 expression is increased
in 91% of proximal tumours. Graph shows
n=90 tumours and n=90 tissue APC min/+ mice. Quantification of LGR5 expression
relative to GAPDH by qPCR in proximal tumours (grey) and tissues (black). Paired Ttest indicates that 91% of samples measured have significantly lower expression of
LGR5 in tumours (p<0.0001). There is a high variability in tumours and tissue.

ZT0

ZT4

ZT8

ZT12

ZT16

ZT20

samples in 89% of distal tumours. Graph shows n=90
Figure 2.14 LGR5 expression is increased

tumours and n=90 tissue APC min/+ mice. Quantification of LGR5 expression relative to
GAPDH by qPCR in distal tumours (grey) and tissues (black). Paired T-test indicates that
89% of samples measured have significantly lower expression of LGR5 in tumours
(p<0.0001). There is a high variability in tumours and tissue.
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Wild-Type
Gene
(Clock gene)

Correlates with
APC min/+
Expression
rhythms?

Peak
expression

Trough
expression

Time-of-day difference in
expression
Anova value

BMAL1
Per2

Slight phase shift
Yes

ZT4
ZT16

ZT12
ZT4

Yes p<0.0001
Yes p<0.0001

REVERB

Yes

ZT8

ZT0

Yes p<0.0001

cyclinD
AXIN2

Yes
Yes

N/A
ZT0,8,16

N/A
ZT4,12,20

No p>0.05
Yes p = 0.0225 (3 peaks/24-hr)

cMyc

No

ZT20

Zt0,16

Yes p = 0.0054

Table 2.1 Summary of results APC+/+

APC min/+
Gene
(Clock gene)
BMAL1
Per2

Tumour vs Tissue
T test value

Time-of-day difference
in expression
Anova value

Higher/ Lower
than Tissue
Proximal - Distal

Peak
expression

Trough
expression

Lower
70% - 90%
Lower
86%-90%

ZT20-ZT0

ZT8-ZT12

Lower p<0.0001

Yes p<0.0001

ZT12

ZT0-ZT4

Lower p<0.0001

Yes p<0.0001
(not in distal tumours

p = 0.726)
REVERB
cyclinD
AXIN2
cMyc
LGR5

Lower
63%-71%
Higher
97%-80%
Higher
85%-82%
Higher
98%-96%
Higher
91%-89%

ZT8

ZT0

Yes p0.0031

N/A

Lower p<0.0001
p=0.0031 tumours
Higher p<0.0001

N/A
Not defined

Not defined

Higher p<0.0001

Yes p0.0092

Not defined

Not defined

Higher p<0.0001

No p>0.05

N/A

N/A

Higher p<0.0001

No p>0.05

No p>0.05

Table 2.2 Summary of results APCmin/+
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2.15 Expression of studied genes at all timepoints. 30 paired tumour and tissue samples at each
timepoint in APC min/+ mice. Graph shows a summary of tumours having less expression than
adjacent tissue (grey) and tissues having more expression than tumours (blue). All expression
levels were normalized to GAPDH. Tumours express less circadian genes than their tissue
counterparts in the majority of samples at nearly all timepoints examined. In contrast, the Wnt
pathway target genes: CyclinD, cMyc, AXIN2 and LGR5 are all more greatly expressed in tumours
compared to their tissue counterparts. These results highlight the lowered circadian clock
function, and heightened Wnt pathway function occurring in APCmin/+ adenomas.
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Chapter 3:
Tumour burden with BMAL1 mutation in the APCmin/+ background
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Results
To test the hypothesis that clock disruption increases tumorigenesis, the APCmin/+ and
BMAL1+/- strains, that are both from the BL6 background, were crossed. Littermates of 4 different
genotypes: APC+/+; BMAL1+/+ (n=12), APC+/+; BMAL1-/- (n=15), APCmin/+ ; BMAL1+/+ (n=11), and
APCmin/+ ; BMAL1-/- (n=12) were collected and examined at 3 months of age. These littermates
were collected between 3-7 generations after the initial crosses in order to achieve offspring with
fewer differences in genetic modifiers that would influence the phenotype. Half were sacrificed
at ZT4 while the other half at ZT12 to test possible time-dependent changes using these samples
at a later date. Intestines were collected as described in the methods for the analyses presented
in this thesis, but blood and stool samples were also collected for future blood hormone and
cytokine analysis and microbiome testing. There is no significant tumour formation in the wildtype APC+/+; BMAL1+/+ as well as in the APC+/+; BMAL1-/- mutant. This indicates that BMAL1
mutation alone does not induce intestinal tumours. In contrast, a 2-fold increase in >1mm size
tumour counts was noted in the APCmin/+; BMAL1-/- compared to their APCmin/+; BMAL1+/+
littermates, and an increase in <1mm size tumours numbers in was also noted in this strain in the
proximal regions of the intestine. This raised the question of whether the loss of BMAL1 in the
CRC background generally increased tumour proliferation. Analyses of tumour size revealed the
size of tumours is greater in the proximal intestine of APCmin/+; BMAL1+/+ compared to APCmin/+;
BMAL1-/-. These results show that BMAL1 loss induces more tumour formation, but does not
impact size in any region of the intestine except the proximal region where tumour size is smaller,
even though the tumours are much more abundant. An explanation for this result could be that
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in the proximal intestine, when BMAL1 is lost, tumours are induces earlier and therefore are
more abundant, but not yet any larger in size.
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Figure 3.1 Total tumour counts in study. Graph shows the number of tumours found in each
individual intestine wholemount. No significant tumours were found in either APC+/+;
BMAL1+/+and APC+/+; BMAL1-/- genotypes. There is a significant increase in the number of
tumours found in APCmin/+; BMAL1-/- mutants compared to APCmin/+; BMAL1+/+ wildtypes (*ANOVA
F (3, 47) = 174.9, p <0.0001).
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Figure 3.2 Tumours counts > 1mm. Graph shows the number of tumours found in each individual
intestine wholemount. No significant tumours were found in either APC+/+; BMAL1+/+and APC+/+; BMAL1/- genotypes. There is a significant increase in the number of tumours found in APCmin/+; BMAL1-/- mutants
compared to APCmin/+; BMAL1+/+ wildtypes (*ANOVA F (3, 46) = 80.63, p<0.0001).
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Figure 3.3 Tumours of < 1mm. Graph shows the number of tumours found in each individual intestine
wholemount. No significant tumours were found in either APC+/+; BMAL1+/+and APC+/+; BMAL1-/genotypes. There is a significant increase in the number of tumours found in APCmin/+; BMAL1-/- mutants
compared to APCmin/+; BMAL1+/+ wildtypes (*ANOVA F (3, 46) = 58.51, p<0.0001).
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Figure 3.4 Tumours of > 1mm size in D regions of intestine are increased in the BMAL1 mutant.
Graph show the number of tumours found in each individual intestine wholemount. There is a
significant increase in size in the distal regions of the BMAL1 mutants (*ANOVA F (7, 84) = 11.09,
p = 0.0013).
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Figure 3.5 Tumours of < 1mm size in P and M1 regions of intestine are increased in the BMAL1
mutant. Graph show the number of tumours found in each individual intestine wholemount.
There is a significant increase in the number of <1mm tumours in APCmin/+; BMAL1-/- mutants
compared to APCmin/+; BMAL1+/+ wildtypes in proximal and medial1 sections (*ANOVA F (7, 84) =
9.69, p = 0.0006 ; ** ANOVA F (7, 84) = 9.69, p = 0. 0337).
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Figure 3.6 Swiss role of BMAL1 wt, APC-induced CRC intestine. Image shows H&E staining of
the APCmin/+; BMAL1+/+ genotype imaged on a slide scanner. Tumours are pseudocoloured in
red. Note tumour size is larger than BMAL1mutant shown in Fig 3.7

Figure 3.7 Swiss role of BMAL1 mutant, APC-induced CRC intestine. Image shows H&E staining
of the APCmin/+; BMAL1 -/- genotype imaged on a slide scanner. Tumours are pseudocoloured in
red. Note tumour size is smaller than wildtype control shown in Fig 3.6
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Figure 3.8 Averages of tumour sizes in µm2. Average Proximal, Medial and Distal (P, M, D) sizes
in both APCmin/+ ; BMAL1-/- and APCmin/+ ; BMAl1+/+. Significantly less tumours size in P region of
APCmin/+ ; BMAL1-/- mice * p = 0.0019 No significance was found in the M and D regions.
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Chapter 4:
Discussion and Future Directives
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Discussion and Future Directives
Our Earth’s rotation creates 24-hour periodicity of day and night - a natural condition that
has influenced all life forms. Organisms that have evolved the best adaptation, meaning they’ve
been able to anticipate timing of their daily activity, have increased their fitness. [14] Efficient
timing of circadian clocks throughout the body helps maintain health of the whole system. [35]
The mouse model is an experimental system that has proven extremely valuable in its capacity
to model human disease. This is largely due to the genetic and genomic similarities between both
organisms. Disease-related genes, such as APCmin/+ causing the initial transformation to an
adenoma, as well as mammalian circadian and Wnt genes are the same in both humans and mice.
Additionally, although the diurnal activity of humans does not directly correspond to the
nocturnal activity of mice, this study does offer insight into how tumours behave and the impact
of the clock on CRC tumorigenesis. This project sought to investigate a) the impact of CRC on
intestinal clock expression and b) the impact on disrupting the clock on CRC progression.

Dampened clock expression
To begin, I found that expression of clock genes BMAL1, Per2, and REVERBα is dampened
in tumours even if they still maintain appropriate rhythmicity. These clock genes have
consistently lower expression in more tumours in the proximal intestines compared to the distal
intestine. The rhythmicity for BMAL1, Per2, and REVERBα are generally similar to the Wt
expression rhythmicity. I can speculate as to the influences in these dampened circadian
expression levels in tumours. Based on research demonstrating that overexpression of cMyc
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attenuates the circadian clock [22] and Myc opposes E-Box-driven expression of Per 1 [36], it is
likely that cMyc is implicated. cMyc is more greatly expressed in tumours in nearly 100% of the
samples. Circadian/metabolism connections have been extensively studied. In cancer,
upregulating cellular signaling pathways involved in cell growth influence energy metabolism. [2]
Could it be possible that the dampened circadian expression as well as the larger percentages of
tumours with a decreased expression are due to different metabolic functions of the proximal
region of the intestine?

Tumour growth and metabolic exploration
Consistent with the findings of cMyc expression, cyclinD is more greatly expressed in a
higher percentage of tumours of the proximal intestine – 97% of proximal tumours have a greater
cyclinD expression compared to 80% in distal tumours. I can speculate that because tumours are
more proliferative (greater cyclinD), there is increased metabolic SIRT1 and clock
downregulation. cMyc may be at a critical cross between metabolism, oncogenesis and a
disrupted clock. I remind the reader that overexpression experiments of cMyc have shown that
Myc;Max are functionally dominant over CLOCK; BMAL1 binding to E-Boxes, which upregulate
repressors components of the clock’s feedback loop, specifically Per2, Cry1 and very importantly,
REVERBα. [23] Per2, Cry1 and REVERB α in turn repress CLOCK and BMAL1 expression in the
feedback loop. Upregulation of cMyc in tumours analyzed may be what is upregulating REVERB
relative to Per2 and BMAL1. Since highly expressed Myc correlates to dampened circadian
expression, and inversely, low expression of Myc correlates to a more robust amplitude in
circadian expression, as is seen in these data, it is possible that Myc greatly contributes to the
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tumour cell’s inhibition of circadian gene expression. Myc is a well-known oncogene that drives
cancer, and adenoma formation in APCmin/+ is blocked when co-deletion of cMyc occurs. [8]
Another study surmised that Myc was a link between oncogenic transformation, metabolic and
circadian dysrhythmia which is advantageous for cancer growth. [23] It would be advantageous
in future to look at metabolomics focusing on glucose, lactate, glutamine or glutamate levels in
tumour and tissue to investigate altered metabolism in correlation with cMyc and Circadian gene
expression. We see in these results, also, that REVERB levels are dampened in tumours, but not
as greatly as Per2 and BMAL1, possibly induced by cMyc as mentioned above. Poor
neuroblastoma prognosis is associated with increased REVERB expression. In a very remarkable
recent study, REVERB agonists were shown to selectively target slowly proliferating tumorigenic
and premalignant cell populations, possibly by blocking metabolic activity in these cells. [37] One
important caveat regarding the interpretation of this study deals with the nature of RNA levels.
Future studies should confirm the findings of this present study by investigation protein levels in
tumours and tissue. There could there be differences in either RNA and the corresponding
protein levels that are not communicated accurately in the investigation RNA levels alone and
given that proteins are the functional components of genes upon their translation in the
cytoplasm, this will be an important next step in the investigation.
Metabolism itself has also been demonstrated to influence clock expression through
SIRT1 via the activity of NAMPT. It is suggested that SIRT is driven by CLOCK; BMAL1 binding to
E-box promoter of NAMPT and a negative feedback loop where SIRT1 then translocated to the
nucleus and blocks binding of CLOCK; BMAL1. [38] It may be that the nature of the proximal
intestinal metabolic function is such that in tumours from this regions, there is a greater
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downregulation of circadian expression. Induction of early-stage transformed cells may have an
earlier onset in the proximal intestine. One observation I made during animal dissections was
that there is a large increase in fat tissue found in both APC +/+ ; BMAL1 -/- and APC min/+ ; BMAL1 /-

mice. Moreover, being overweight or obese is linked with an increased risk of many types of

cancer, including CRC. [39] These observations suggest BMAL1 loss drives obesity and could
provide a basic insight into the metabolic dysrhythmia associated with cancer in the predisposed
CRC in the APC min/+ mouse without circadian machinery.

Clock deregulation and tumorigenesis
As mentioned in the introduction, earlier research had shown that Per1 gene was
necessary for effective DNA damage repair and reduced growth in cancer cells [21], and another
found increased Per2 prevented tumour growth. [20] Others found Per3 was downregulated in
chronic myeloid leukemia [28] while another concluded that Per2 mutant mice had a neoplastic
phenotype and were cancer prone. [27] These older studies have been more recently challenged
in findings where the investigators found cell lines with mutations in the circadian machinery
were indistinguishable from their wild-type counterparts when it came to DNA damage response
[39] Also, other research revealed errors in the methodologies of the earlier Period investigations
using careful backcrossing of mice carrying the Per mutations on the same genetic background.
[33] [34] The overall implication of these failure to replicate studies, is that single Period gene
mutations cannot drive cancer.
There are additional reasons why the clock cannot be implicated in these early Period
mutant studies. Period genes have 3 homologs in mammals. If one is missing, others will
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compensate for their loss and rhythmicity will still occur. In other words, missing one of the
Period genes does not constitute a clock-dead model (Period proteins also have non-clock
functions). It thus seems likely that the tumorigenicity observed was a result of unknown
oncogenic activation or tumour suppression inactivation in their genetic background. My findings
support these newer reports. I found no increase in tumour formation in the BMAL1-/-mutant
mice. However, this fails to address whether truly clock-dead mice would develop spontaneous
carcinogenesis when aged. Cry1-/- and Cry2-/- mice irradiated at 8 weeks were indistinguishable
to Wild type mice as were Per1-/- and Per2-/- mice in 2 separate and more recent studies. [33]
Therefore, observing BMAL1-/-mice for 80-90 weeks would shed light on tumorigenesis in this
population. Based on this study, it appears that another underlying genetic mutation
predisposing an animal to cancer, such as loss of APCmin/+, is necessary for the circadian clock to
promote tumour induction. Another important consideration for results from this study is that
while reducing genetic variation between samples by backcrossing for 4-5 generations was
important, this reduction was not enough to eliminate absolutely the possibility of having other
genetic variability affecting our results. Many generations more of backcrossing would need to
occur for the results to be completely eliminate phenotype modifiers. A next step in the
investigation of clock genes and CRC would be to investigate clock gene expression in different
known stages of tumours – possibly human samples – in order to better elucidate changes in
clock gene expression in the adenoma-carcinoma progression.
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BMAL1
Previous studies have manipulated the gene BMAL1 in the context of cancer. It was
identified that AML cells needed increased BMAL1 expression in order to proliferate and its
downregulation halted proliferation. [32] These were studies in cell culture contrastingly to this
study, which is in vivo, whole animal. Although not directly comparable due to the difference in
nature of the two kinds of studies, it does offer a disagreement with the findings of my research.
It could be that the AML findings were tissue or cell specific or that it was a result of the isolation
of cells in vitro. Alternatively, in vivo systemic alteration in the clock implicating a myriad of
interactions that occur in the whole organism could be at play for the increased induction of
tumours that I have discovered. Of course, my results, which tested the whole mutant BMAL1
animal, are also a source of error as these effects could be taking place anywhere in the body or
during its development. Also and as mentioned previously, 3-7 generations of backcrossing was
likely not sufficient to remove any modifiers in the genes that may influence phenotype. Early
induction of tumour phenotype may be at work here. In order to accurately investigate the tissuespecific impact of the clock and intestinal tumorigenesis, future studies will need to investigate
BMAL1 floxed mice with conditional KO in intestinal epithelium only and also only after
development. Two strains of mice would need to be crossed: mice with cre recombinase driven
by a Villin promotor and BMAL1 Fl/Fl. This would test BMAL1 loss in the intestinal epithelium only.
If a Villin-CreERT2 strain was used, mice could be injected with tamoxifen during only adulthood
to conditionally delete BMAL1 in the intestine and avoid developmental effects. In both of these
conditional experiments, these mice would have intact SCNs and all other peripheral clocks, just
not in the intestine. Finally, another follow-up experiment that could also test a disrupted clock
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and its impact on tumorigenesis would be to disrupt photoperiods in mice and/or restricted
feeding in APCmin/+ mice without BMAL1 mutation. The results of these studies could be compared
and informative to see if the effects I observed were due to clock function in non-intestinal
tissues, or during development.
It is possible the tumour increases I observe are due to non-autonomous effects, so
experiments complementary to the conditional KO would be informative. Additional insight
would be to analyze the microbiome in BMAL1 -/- comparatively to BMAL1+/+. It was collected in
this project, but not yet analyzed. It will be an important addition since it may elucidate if the
intestinal flora population in the intestine of clock-dead mice differs from the Wt counterpart
and if this somehow correlates to tumorigenesis. I also collected blood for analysis of
corticosteroids and serum to investigate systemic pro-inflammatory cytokines from each cohort
in efforts to tease out stress responses and inflammatory responses in tumorigenesis in clockdead mice.

Stem cell marker LGR5
LGR5, the ISC marker, has also been explored in hopes to unveil if tumours are an
undifferentiated cell population. The tumours express greater LGR5 compared to the adjacent
tissue – 90% of tumours have greater LGR5 expression. Likely, the cells of these tumours are nondifferentiated, even if they have moved above the differentiation line at the top of the crypts.
Could this be due to an “inverted” crypt formation up into the villi – due to a perceived continual
Wnt signaling from the extracellular environment? The lack of cellular differentiation and
subsequent proliferation sets up the stage for additional replication errors, deregulated
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metabolism, deregulated apoptotic measures from the cell and transformation. Future
investigation looking at Rspondin levels in the cell population of CRC adenomas could help with
understanding if Paneth cells also populate the adenoma, sending these Wnt agonists for
sustained growth.

Tumour numbers vs. size
H&E staining allows us to scan and make precise measurements of the tumours’ areas (in
µm2) from 10µm slide sections. In accordance with the increased tumour numbers between both
groups that is observed, random sections on slides from APCmin/+ ; BMAL1+/+ samples have 23 and
24 tumours located and measured in the proximal and medial intestines, respectively, while
APCmin/+ ; BMAL1-/- have 59 measured distinct tumours in both respective regions – approximately
2.5 times more tumours on these slides. In the distal regions of both cohorts, there is no
significant difference in number of tumours found for measurement. This coincides with the
increase in tumour numbers found during wholemount counting. However, although the
proximal region for the BMAL1 mutants have more tumours, their sizes, in general, are
significantly smaller. The increase in tumour numbers – especially in the proximal intestinal
region – with a smaller average size was indeed a surprise finding. When whole mounting and
counting the tumours in APCmin/+ ; BMAL1-/- , my recurrent general observation was that there
were many more tumours, but there were often very small in size. Why could there be more ,
but those present smaller? If it were a growth inhibition, tumour numbers would be similar
between BMAL1+/+ and BMAL1-/- , but the former has fewer tumours that are, on average,
greater in size. It is possible that a BMAL1-/- mutation induces earlier adenoma formation,
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accounting for their increased numbers, but decreased size in general. These results suggest that
the loss of BMAL1 affects tumour induction, but not proliferation, generally, in advancing
tumorigenesis. There are many mechanisms that would explain this including changes in the
number of stem cells and/or Wnt signaling, and changes in DNA damage response – both
possibilities are worth examining in future work.

Conclusion
I found that expression of clock genes BMAL1, Per2, and REVERBα is dampened in
tumours even if they still maintain appropriate rhythmicity. Conversely, Wnt target genes AXIN2,
cMyc and cyclinD all more greatly expressed in adenomas. The stem cell marker LGR5 is also more
greatly expressed in adenomas, implying an inverse affiliation between the circadian clock and
growth. There are more tumours in the APCmin/+ CRC model system when BMAL1 is lost, but these
tumours are not greater in size, suggesting that tumours suppress the circadian clock and that its
complete loss promotes tumour numbers.
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